Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Contrafect (CFRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
ContraFect Announces Oral Presentation at the 2019 Gordon Research Conference on Mechanisms and Application: Realizing the Potential of Antimicrobial Host Defense Peptides for Human and Veterinary Medicine

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious...

CFRX : 0.44 (+2.33%)
These 4 Healthcare Stocks Are Raising Expectations

CORAL GABLES, FL / ACCESSWIRE / January 17, 2019 / The future of , and the medical sector industry as a whole, is predicated on the notion that as diseases become more advanced and difficult to treat,...

CFRX : 0.44 (+2.33%)
PHGI.CN : 0.830 (unch)
CRMD : 1.69 (-5.06%)
PHGRF : 0.6316 (+1.95%)
LMFA : 1.38 (+1.47%)
Antimicrobials Working Group Announces Updates to Leadership Team

The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer of Paratek Pharmaceuticals, Inc. Dr....

MLNT : 1.38 (-7.38%)
ITRM : 5.80 (-3.33%)
CFRX : 0.44 (+2.33%)
MTFB : 2.69 (-4.27%)
SMMT : 1.25 (-2.34%)
SCYX : 1.38 (+0.73%)
CDTX : 2.53 (+2.43%)
NBRV : 2.06 (+1.48%)
PRTK : 7.23 (+0.70%)
ContraFect Announces Additional $2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious...

CFRX : 0.44 (+2.33%)
ContraFect to Present at Biotech Showcase 2019

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious...

CFRX : 0.44 (+2.33%)
ContraFect to Present at Piper Jaffray Health Care Conference

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious...

CFRX : 0.44 (+2.33%)
ContraFect Announces Third Quarter 2018 Financial Results

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious...

CFRX : 0.44 (+2.33%)
ContraFect to Present at 2nd International Symposium on Antimicrobial Hydrolytic Enzymes

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious...

CFRX : 0.44 (+2.33%)
ContraFect Announces First Quarter 2018 Financial Results

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious...

CFRX : 0.44 (+2.33%)
ContraFect to Present CF-301 Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious...

CFRX : 0.44 (+2.33%)
Glancy Prongay & Murray LLP Announces Investigation on Behalf of ContraFect Corporation Investors (CFRX)

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of ContraFect Corporation (NASDAQ: CFRX) investors concerning the Company and its directors' and officers' ...

CFRX : 0.44 (+2.33%)
ContraFect Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious...

CFRX : 0.44 (+2.33%)
ContraFect to Present at the 20th Annual Superbugs & Superdrugs UK Conference

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious...

CFRX : 0.44 (+2.33%)

Van Meerten Stock Picks

SecureWorks - Pick of the Day
My Stock Pick of the Day belongs to the security software company SecureWorks (SCWX).
SCWX -0.33
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar